EPISODE · Jun 13, 2026 · 23 MIN
June 13 2026-Extraordinary Breakthroughs in Cancer Treatment & A Deep Dive Into Creatine
from Zoomer Week in Review · host Zoomer Podcast Network
It has been a season of extraordinary breakthroughs in the treatment of cancer. From a game-changing drug for pancreatic cancer - the most intractable of diseases - to a major advance in lung cancer - to mounting evidence that GLP-1 drugs can prevent cancer or delay its spread. I spoke to Dr. Malcolm Moore, medical oncologist at Princess Margaret Cancer Centre and a former head of BC Cancer, He told me about the groundbreaking research that was highlighted at the recent American Society of Clinical oncologists annual conference (ASCO). And It’s the supplement everyone’s talking about and the evidence shows that buzz around creatine is more than just hype. It targets one of the biggest problems as we age - losing muscle mass - I spoke with one of leading researchers on its benefits Dr. Mark Tarnopolsky of McMaster University.
What this episode covers
It has been a season of extraordinary breakthroughs in the treatment of cancer. From a game-changing drug for pancreatic cancer - the most intractable of diseases - to a major advance in lung cancer - to mounting evidence that GLP-1 drugs can prevent cancer or delay its spread. I spoke to Dr. Malcolm Moore, medical oncologist at Princess Margaret Cancer Centre and a former head of BC Cancer, He told me about the groundbreaking research that was highlighted at the recent American Society of Clinical oncologists annual conference (ASCO). And It’s the supplement everyone’s talking about and the evidence shows that buzz around creatine is more than just hype. It targets one of the biggest problems as we age - losing muscle mass - I spoke with one of leading researchers on its benefits Dr. Mark Tarnopolsky of McMaster University.
NOW PLAYING
June 13 2026-Extraordinary Breakthroughs in Cancer Treatment & A Deep Dive Into Creatine
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m